Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 April 2025 | Story Precious Shamase | Photo Supplied
Ennie Mkotywa
Ennie Mkotywa celebrates her graduation at UFS Qwaqwa Campus, marking a triumph of resilience, passion, and lifelong learning.

Ennie Mkotywa walked across the stage in the iconic Mandela Hall this morning, Friday 4 April, graduating with a Bachelor of Arts Degree (Honours) specialising in English. This is a testament to the power of passion, perseverance, and the transformative potential of education. Working as an assistant officer in the Centre for Teaching and Learning (CTL), Ennie's story is one of balancing professional responsibilities with academic aspirations – a journey that has culminated in a remarkable achievement.

 

Passion ignited

Mkotywa’s love for literature began in high school, blossoming during her undergraduate studies where she excelled in literary analysis. "I've always been passionate about reading books and poetry," she recalls. "During my undergraduate studies, I discovered that I was good at analysing literature, which led me to become a tutor." However, financial constraints initially delayed her pursuit of an honours. It was her appointment at CTL that reignited her dream, as she discovered the study benefits available to staff.

 

Balancing act and triumph

The journey was far from easy. "The most challenging part was balancing work, studies, and personal life," Ennie admits. "Juggling work deadlines with academic responsibilities was incredibly difficult." Working in a student-facing role, finding time for study was a constant challenge, requiring her to dedicate evenings to her coursework. Yet, the rewards were profound. "The most rewarding aspect was submitting my research and passing. Receiving my results was one of the happiest moments of my life."

 

Inspiration and mentorship

Ennie credits Dr Nonki Motahane from the Department of English as a significant source of inspiration. "Dr Motahane's journey resonates deeply with me," she says. "Witnessing her growth from a master's candidate to a PhD holder has been incredibly motivating." This mentorship fuelled Ennie's own academic aspirations, demonstrating the power of role models within the UFS Qwaqwa community.

 

Decolonial analysis and insight

For her honours research, Ennie focused on a decolonial literary analysis of Yewande Omotoso's Bom Boy (2011). Her dissertation, ‘Images of a Democratic South Africa: A Decolonial Analysis of Yewande Omotoso’s Bom Boy (2011)’, explored the contradictions within South Africa's post-apartheid ‘rainbow nation’ agenda. "My research portrays the enduring racial and socioeconomic inequalities in post-apartheid South Africa," Ennie explains. Her analysis highlighted the persistent colonial structures and the failure to achieve true equality and inclusivity.

 

Transformative impact and future aspirations

Ennie's studies have had a profound impact on her perspective, particularly regarding the #FeesMustFall movement. "Researching for my honours allowed me to understand the movement’s significance and the concept of decoloniality," she shares. Her enhanced English skills will benefit her work at the Write Site, supporting students with academic writing, and align with Vision 130's goal of increasing research output.

Looking ahead, Ennie plans to pursue a master’s degree and a PhD, aiming to deepen her expertise and expand her career opportunities.

 

A message of lifelong learning

Ennie's advice to fellow UFS Qwaqwa Campus staff is to embrace lifelong learning. "Pursuing further education is a powerful way to enhance your professional and personal growth," she says. "Take advantage of the resources and support systems available at the UFS, and don’t be afraid to reach out for help."

 

Community and support

Ennie emphasises the strong sense of community on the UFS Qwaqwa Campus. "The Department of English, my supervisor Dr Peter Moopi, and my colleagues were incredibly supportive," she notes. "The library services and the shared experiences with fellow students were invaluable." She also recounts a story of a librarian remembering her when she was waiting for a book from Bloemfontein, and how that personal touch meant a lot.

 

Resilience and triumph

Even when faced with challenges, such as a difficult lecturer, she persevered. "Looking back, I realise that such experiences are the ones that build resilience," she reflects.

Mkotywa’s graduation is not just a personal achievement; it is a testament to the supportive environment on the UFS Qwaqwa Campus and the transformative power of education. Her story serves as an inspiration to the entire university community, proving that with dedication and support, any goal is achievable.

As a parting shot: "Remember that the process may sometimes be difficult, but the results are transformative. Stay focused on your goals and trust in the value of the journey, because the experience of learning is just as important as the final achievement." – Ennie Mkotywa.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept